Micromax adds ‘third screen’ to its portfolio; Unveils new range of LED TVs
Ø Sets up a production unit at Rudrapur, Uttrakhand with a production capacity of 2,000 LED TV units per day
Ø To make products available in 9 states with a strong distribution network, reaching out to 170 cities
New Delhi, October 09, 2012: Micromax, the largest Indian handset manufacturer and the 12th largest handset manufacturer in the world, today announced its foray into the home entertainment segment with the launch of new range of LED TVs, Home Theatres, 3D Blu Ray and SMART Stick, the Android dongle which will make TV viewing a smart experience.
With this launch, Micromax aims to become the new age screen partner for consumers; be it phones, tablets or televisions. Micromax has set up a 1 lakh sq. ft. of manufacturing facility spread over 5 acres, with a production capacity of 2,000 LED TV units per day at Rudrapur, Uttrakhand. The facility will also double up to manufacture the tablet PC Funbook and mobile accessories, which in the last 6 months has received tremendous response.
Commenting on the launch, Rajesh Agarwal, Managing Director and Co-Founder, Micromax, “Micromax is increasingly focusing on the smart devices and has introduced a series of Android powered devices in the screen range of 5” to 10”. As we move forward, we want to be the Screen partner for our consumers, no matter what the screen size is. As consumer preferences evolve and they want their devices and experience to be smart and personal, we feel the future of TV will depend on user, programming, connectivity and personalization. Compared to mobile phones, Televisions are a long-term interface and consumers want these to be smart and Sauvé and at the same time have a seamless experience while shifting from one screen to another. With Micromax TVs, we aim to partner the growing aspirations of the digital consumers at all levels.”
Mukesh Gupta, Director, Micromax said “TV is a dynamic component in ones living room and we aim to make this experience better and more personalized by providing features which delivers cinema like experience at home. Adding to the consumers delight, we have also introduced a new range of Home Theatre system with 5.1 surround sound speakers, a 3D Blu Ray Player, which supports both 2D and 3D content and an Android dongle- Micromax SMART Stick. The SMART Stick is aimed at consumers who wish to take their television viewing a notch higher by converting it into an Android TV.”
Adding to this, Sunil Dutt Sharma, Business Head (Consumer Electronics), Micromax said, “We have created strong brand equity through our handheld devices and have added value to our consumers. We are targeting aspirational buyers, who want to upgrade their television viewing and at the same time demand value. We plan to introduce our offerings initially in 9 key states i.e. Delhi, Haryana, Madhya Pradesh, Punjab, Maharashtra, Rajasthan, Andhra Pradesh, Karnataka and Gujarat. We will deploy a two-tier distribution channel which will help us to reach out to 170 cities and build a strong consumer connect. For the Large Format Retail, we have tied up with BrightPoint.”
The LED TVs will range from 24” to 55” and will be competitively priced between Rs. 15,990 and Rs. 1,29,990. All 6 models feature High Definition Media Interface, which supports all video resolution. Powered by AVEA (Audio Visual Entertainment Architecture), Micromax LED TV features the best picture quality and the finest cinematic sound through an in-built powerful sound system, which will take TV viewing experience to another level.
Pricing of the 6 models of LED TVs are mentioned below:
|
S.no
|
Model no
|
Key feature
|
Size
|
MRP (INR)
|
|
1
|
LEDT770K55F
|
3D, full HD, Smart TV
|
55 inch
|
1,29,990
|
|
2
|
LEDK316K50F
|
3D, full HD
|
50 inch
|
79,990
|
|
3
|
LED42K316
|
Full HD
|
42 inch
|
47,990
|
|
4
|
LED32K316
|
HD
|
32 inch
|
25,990
|
|
5
|
LEDL31FL24F
|
Full HD
|
24 inch
|
16,990
|
|
6
|
LED24K316
|
HD
|
24 inch
|
15,990
|
Key highlights of LED TVs are:
Live High-Definition with Micromax LED: The Micromax LED TV powered by AVEA (Audio Visual Entertainment Architecture), offers full HD resolution and dynamic contrast coupled with amazing image detail, color clarity and crystal clear HD surround sound.
HDMI and USB connectivity: Micromax LED TV’s supports all video resolution and connects to all devices through the HDMI. They also feature a plug and play USB port. These USB ports can play almost any format of music files; videos connect mp3 player, digital camera, hard drive etc. to the ports for instant connection. The USB port supports 14 kinds of formats across all audio and video files.
Ultra low Power consumption: Compared to normal CRT, it saves 70% more power and compared to other LCDs, it saves 40% more power
Digital audio output: Micromax TV delivers the most powerful audio quality, through its digital audio output feature. While analog audio is suitable for 2 speaker systems only, digital audio output allows the audio to be split up to 8 speakers.
Zero bright dots LED panel: With its zero bright dots LED panel, Micromax TV ensures best in picture performance. The panels used in lower series in other televisions may have 2 to 5 bright dots permanent on their panel which is not detectable by the naked eye, but it results in poor picture quality near the bright dots, whereas the Micromax panel is equipped with 100% zero bright dots.
Large format display: The 55” LED from Micromax will be a smart TV and will be equipped with technologies such as IPTV applications which will enable consumers to connect with the world in a smart way. Both 50” and 55” offers eco-friendly LED technology with 3D viewing experience. Besides, 3D content and internet connectivity, these LED are bundled with features for a unique television viewing experience such as:
- Full HD 1920 x 1080 Pixel screen resolution for clear an crisp image
- 100Hz refresh rate for faster performance
- 400nit brightness
- 176/176 viewing angle in 50” and 178/178 in 55”
- Backlight control
- Zoom function with: 4:3, 16:1, Auto, Zoom 1, Zoom 2
- Program and Child lock for restricted viewing
- Digital media player (DMP) for music, video and photos and text
- Audio equalizer with sub woofers (55”)
- Pack of 4 3D glasses
Micromax SMART Stick: Micromax accessorizes its LED range with a dongle powered with Android 4.0.3 (Ice cream Sandwich), worth Rs. 4,990. It offers a frequency of 1.0 GHz which offers GPU offers 3D graphic with OpenGL ES2.0 and OpenVG 1.1. It has a Standard HDMI Interface, Internal 4 GB Nand Flash, Wi-Fi direct connection and USB HUB. Additionally, it supports RF 2.4 GHz Mouse, Keyboard and Game PAD.
3D Blu Ray Player which supports all 2D and 3D video/ Audio formats, comes at an attractive price of Rs. 6,490.
About Micromax:
Micromax is No.1 Indian tablet manufacturer* and the 12th largest handset manufacturer in the World ** The Indian brand is reaching out to the global frontier with innovative products that challenge the status quo that Innovation comes with a price. Micromax has sales presence across India and global presence in Hong Kong, Bangladesh, Nepal, Sri-Lanka, Maldives, UAE, Kingdom of Saudi Arabia, Kuwait, Qatar, Oman, Afghanistan and Brazil.
AirAsia Japan Launches International Flights to Korea
Posted on October 10, 2012 by sagarmedia
AirAsia Japan Launches International Flights to Korea
Edit Published October 10, 2012 by sagarmedia
Steady Nalini takes two-shot lead in Hero-Classic Golf Resort Women’s golf
Gurgaon, October 10: Nalini Singh Siwach maintained her steady form with a fine even-par round of 72 to take a two-shot lead at the end of the first round of the Hero-Classic Golf Resort Women’s Pro Golf, the eighth leg of the Indian women’s domestic Tour. She was two shots clear of Saaniya Sharma, who is still looking for her first win this season.
Smriti Mehra, winner of three titles this year, paid for her triple bogey eight on the par-5 third hole to finish at 75 and three behind the leader. She was tied for third with Vani Kapoor.
Nalini, who has already won once on the Hero-WGAI Tour, had three birdies and three bogeys. She bogeyed the seventh but got that back on the very next hole to turn in even par. On the back nine, a birdie on par-3 11th got her under par, before she gave away bogeys on 13th and 15th, but a closing birdie on 18th saw her finish at even par.
Saaniya Sharma, who has time and again given away the advantage, had one birdie against three bogeys in her two-over 74.
Vani Kapoor, winner last week at Delhi Golf Club, birdied the third, but then had back-to-back bogeys on fifth and sixth and then again on 15th and 16th. The rest were pars in her 75.
Neha Tripathi with one birdie, four bogeys and one double bogey carded 77 and was fifth, while Meghna Bal, Nikki Ponappa and Rani Sonti were sixth at 78.
On the Money List Smriti has won Rs. 7,67,750 this year, while Nalini has Rs. 6,98,000. Vani is just behind with Rs. 6,72,250 in third place.
This season Smriti has won three times, while Vani has won once. Sharmila and Nalini have won once each.
Tee times for Second round
8:30 AM: Seema Sobti (85) / Pallavi Jain (83)
8:40 AM: Preetinder Kaur (80)/Shraddhanjali Singh (80)/Ankita Tiwana (80)
8:50 AM: Priya Puri (79) / Rani Sonti (78) / Nikki Ponappa (78)
9:00 AM: Meghna (78) / Neha Tripathi(77) / Vani Kapoor (75)
9:10 AM: Smriti Mehra (75) / Saaniya Sharma(74) / Nalini S. Siwach(72)
To get more info on Hero Women’s Professional Golf Tour please visit us on our websitewww.wgai.co.in and join us on Facebook or follow us on Twitter or contact Abhoy Chattopadhyay / Deependra Chetri on +91 98113 25251 / +91 98111 82106.
–
Posted 1 minute ago by Nksagar
0
Add a comment
Oct
10
Description: SANOFI_Logo_H_2011_Quadri copie
Sanofi launches specially designed ‘made in India’ re-usable insulin pen – AllStar™
- Only multinational company in India with (a) a balanced portfolio of orals and insulins (b)one of the longest running national patient counseling programs and now…. (c) a chic indigenously manufactured re-usable insulin pen with 10-in-1 features, specially designed for Indians-
New Delhi, October 10, 2012: Sanofi India Limited (formerly known as Aventis Pharma Limited) announced today the launch of AllStar™, its first indigenously manufactured re-usable insulin pen. Developed especially for Indian patients by Sanofi’s Medical Device Development team at Frankfurt (architects of Sanofi’s award winning devices such as the Solostar®, Clickstar®, BGStar® and iBGStar™), AllStar™ is indicated for use of insulinized patients using Sanofi’s insulin portfolio. The AllStar™ re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the-art, unparalleled 10-in-1 features.
AllStar™ re-usable insulin pen’s 10-in-1 features – (1)Slim & discreet (2)Clear dose magnification window (3)Dose arrow on both sides (4)Bayonet cartridge lock (5)Short dial out distance (6)Penalty– free reverse dialing (7)Maximum dose dialing of 80 units (8)Audible click sound with every unit dialed and dispensed (9)Stops at 300 units (10)Non-rotating dial button during dispense Insulin therapy is a one of the cornerstones of diabetes management, and its efficacy in early as well as late-stage diabetes is well-established. Yet, the first choice of doctors in India for most diabetics has so far been to attempt sugar control through OADs (Oral Anti-Diabetics), diet control, exercise and lifestyle changes. One of the key reasons for delaying control through insulin is the resistance and fear in patients, of taking injections daily, particularly self-administering the same. AllStar™ is custom-made for patients in India. AllStar™ will help improve both insulin initiation and compliance; and bring ease and reassurance to the lives of Indian patients, giving them the convenience of international standards at an affordable price.
Announcing the launch of AllStar™, Dr. Shailesh Ayyangar, Managing Director, Sanofi India & Vice President South Asia, Group Sanofi, said, “Sanofi has always been at the forefront of diabetes research and development and AllStar™ is a testament to our patient-centric approach. For almost three years, Sanofi’s scientists worked closely with our team here to develop a device that was ‘made in India, for India’.”
Dr. Ayyangar further added “AllStar™ heralds a new era of indigenous device manufacturing for Sanofi India, which we hope to utilize for other devices in future.
‘The launch of AllStar™ is a significant milestone in Sanofi India’s diabetes growth story, and also underlines the Sanofi Group’s focus on diabetes, emerging markets and our regionalized approach to finding solutions that are adapted to local needs.“
Commenting on the genesis of this development, Susheel Umesh, Head of Commercial Operations, Sanofi India, said “In line with our mission to truly become a 360 degree partner in diabetes management, we always start with the patient, to understand from them and their physicians what their real needs and expectations are, and work towards introducing solutions to address those needs and expectations.
‘AllStar™ is the result of a successful collaborative multi-country effort within the Sanofi Group that brought together technology, resources and intellectual capital to help Sanofi India develop a pen that its patients aspire for; one that combines convenience and affordability.”
Through a perception study done in July 2011[i], Sanofi found that the most valued features of an insulin pen are ease of use, readability of dose, reverse dialing and high quality. At that time, the study group perceived AllStar™ as better than other pens in the market on most parameters, with ease of use, lighter, smaller and slimmer design being the key differentiators.
All Star™
Speaking on the AllStar™ pen’s technical aspects, Dr. Volker Korger, Head – Diabetes Device Projects, (MED Frankfurt) Sanofi, shared that, “AllStar™ is a combination of sleek design styling and sophisticated technology. We brought together Sanofi’s award winning Solostar® design team in Germany and UK to make AllStar™, the lightest reusable insulin pen in India. The German team contributed its renowned expertise in quality medical devices, and from Taiwan we included accurate tooling, as in a device such as this, extraordinary accuracy is most vital in even the smallest of components. Finally, the manufacturing is being done in India – well recognized today for producing high-precision components.”
With close to 62 million diabetic patients, of whom many are either undiagnosed or uncontrolled because of poor compliance, diabetes is a major health problem in India. Given the social and economic impact of diabetes, it is important to make concentrated efforts to help create awareness about diagnosis, management and treatment of diabetes and further, to re-inforce among physicians and patients the necessity of preventing complications in diabetic patients through early insulin therapy.
Dr. S.K Wangnoo, Senior Consultant, Endocrinology and Diabetes, Apollo Centre for Obesity Diabetes and Endocrinology, Indraprastha Apollo Hospitals said, “Various studies have established the importance of early insulin therapy in the management of diabetes. Key to ensuring better compliance and management at the patient level is providing them with convenient solutions. AllStar™, a state-of-the art device for the administration of insulin, will provide Indian patients with the ease of self-administration, and bring comfort and efficacy into their lives.”
AllStar™ is supported by a patient support team of certified diabetes educators to assist patients under guidance of treating physicians, and a toll-free number. The re-useable AllStar™ will be available for use with Sanofi’s insulins – Lantus® and Insuman® – on doctor’s prescription at all leading chemists and distributors across India.
Susheel Umesh added, “We are striving to help people manage the complex challenge of diabetes by delivering and enabling access to a range of innovative, personalized solutions, because we want people to live ‘beyond’ diabetes, to achieve aspirations and make the most of everyday!”
About Diabetes: Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million persons worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. World Health Organization (WHO) estimates that India had 32 million diabetic patients in the year 2000 which would increase to 80 million by 2030. The International Diabetes Federation has reported that the 50.8 million diabetic patients in India in 2010 would rise to 87 million by 2030. These observations clearly evince that diabetes has become a major health problem in India.
About Sanofi: Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
In India, Sanofi operates through five entities − Sanofi India Limited (previously known as Aventis Pharma Limited), Sanofi-Synthelabo (India) Limited, Sanofi Pasteur India Private Limited, Shantha Biotechnics Limited and Genzyme India Private Limited.
About Sanofi Diabetes:
With a century of experience in Diabetes, Sanofi stands committed to improve the lives of people with diabetes. Through its various incarnations, Sanofi has led the field in insulin manufacturing as well as in diabetes research and development: from the first manufacture of insulin (one of its predecessor companies, Hoechst, was the original company to produce insulin in 1923, after the discovery by Frederic Banting and Charles Best in Canada that insulin could be extracted and initially used to treat children with Type 1 diabetes ) through to the development of Lantus® (the first company to produce a long-acting basal insulin analogue) launched a decade ago and up to the present day, where it is now investigating the possibility of regenerating the insulin-producing cells in the body.
In addition to its insulin products, Sanofi has a range of award-winning delivery devices, oral therapies – on the market and in development – and innovative blood glucose monitoring systems, so that, together with its personalized services, Sanofi can offer a patient-centric partnership to people with diabetes.
Aligned to the Sanofi Group’s commitment to diabetes, Sanofi Diabetes India strives to become a true 360 degree partner for patients and healthcare professionals, offering a complete range of innovative and integrated solutions.
MEDIA CONTACT:
Ms. Ambereen SHAH Account Director Tel: +91 9717022731 Email: bhavna.thapar@edelman.com Shilpy ROY Account Manager Tel: +91 9650111652 Email: shilpy.roy@edelman.com Sanofi India Agency: Edelman India
Ruchita MEHRA
Head – External Communications
Tel: +91 98209 86056/ 022-28278233
Email: ruchita.mehra@sanofi.com
Nikita MERCHANT
Assistant Manager – Marketing Communications
Tel: +91 9819071300
Posted 17 minutes ago by Nksagar
Oct
AirAsia Japan Launches International Flights to Korea
Fly from Narita to Seoul from as low as KRW2,000 one way
TOKYO, 10 October 2012 – AirAsia Japan, an affiliate of the world’s best low cost carrier for four consecutive years is set to strengthen its position as an industry leader with the announcement of its international route to Seoul (Incheon), Korea. In conjunction with the international flight debut celebration, AirAsia Japan is having a special promotion with seats from as low as KRW2,000* up for grabs.
The Narita to Seoul (Incheon) route will begin operations on October 28th 2012 with daily flights operating from Narita International Airport.
Seats between the Narita – Seoul (Incheon) route are from as low as KRW30,000 one way, inclusive of airport tax and fees. Guests are able to grab the special promotional fares exclusively at www.airasia.com beginning 10pm (GMT+8) on 10 October till 17 October 2012 for the travel period from 28th October – 30th March 2013.
The new route announcement was made simultaneously by AirAsia Group CEO Tony Fernandes in Seoul and AirAsia Japan CEO Kazuyuki Iwakata in Tokyo.
Tony said, “This is a great day for all of us, and an even greater day for the consumers & air travelers in Korea. With AirAsia’s low fare, everyone can now travel to more places more often. AirAsia Japan’s announcement of this international route today is a dream come true for us, and I am looking forward to see the Narita – Incheon flights begin operations. Congratulations to Kazuyuki and his team for making Japanese and Korean skies friendlier and more affordable.”
Kazuyuki said, “We are extremely happy and proud to enable so many guests to fly and enjoy the AirAsia experience since we started operations about three months ago. The announcement of our new international routes to Korea gives me much pleasure as AirAsia Japan can now further expand the AirAsia Group’s existing extensive route network, connecting Japan and other countries in Asia. It makes much sense to begin our international flights to Korea, our next-door neighbor and I am sure that this will further enable and inspire more people to travel to international destinations as the flights take only about 2 hours from Narita to Incheon.
AirAsia Japan’s international flights will also be operated on Airbus A320 aircraft with a capacity of 180 seats, similar to its domestic flights.
Follow AirAsia on social media via Facebook (http://www.facebook.com/AirAsiaKorea) and Twitter (http://www.twitter.com/airasiakr) for latest updates, promotions, activities and more.
*KRW2,000 base fare is not inclusive of airport tax and fees.
Tokyo（Narita）⇒Seoul（Incheon）
Seoul（Incheon）⇒Tokyo（Narita）
Flight No.
10/28～3/30
Flight No.
10/28～3/30
ETD
ETA
ETD
ETA
JW 0893
14:15
17:00
JW 0892
17.45
20:00
Photo captions:
Photo 1 – AirAsia Group CEO Tony Fernandes and AirAsia Group Head of Commercial Kathleen Tan (5th from left) announcing AirAsia Japan’s new international route in Seoul, Korea
Photo 2 – AirAsia Group CEO Tony Fernandes and AirAsia flight attendants at AirAsia Japan’s Narita – Seoul international route launch in Seoul, Korea
Photo 3 – AirAsia Japan CEO with AirAsia flight attendants during the Narita-Seoul international flight announcement in Tokyo. AirAsia Group CEO Tony Fernandes made a simultaneous announcement in Seoul, Korea
About AirAsia Japan & AirAsia Group
AirAsia Japan is a joint-venture between ANA and AirAsia, which was established in August 2011. As a low-cost carrier (LCC) based in Narita International Airport, it operates domestic routes to Sapporo, Fukuoka, & Okinawa since August 2012 and will start to operate international routes to Seoul and Busan in Korea in October 2012. AirAsia Japan’s objective is to develop the LCC market in Japan, generating new demand with the aim of making affordable and quality travel available to all. AirAsia Japan is part of the AirAsia Group, the leading and largest low-cost carrier in Asia servicing the most extensive network with over 150 routes. Within 10 years of operations, AirAsia has carried over 150 million guests and grown its fleet from just two aircraft to approximately 106. AirAsia was named the World’s Best Low Cost Airline in the annual World Airline Survey by Skytrax for four consecutive years (2009, 2010, 2011,2012).
Edit Published October 10, 2012 by sagarmedia
Steady Nalini takes two-shot lead in Hero-Classic Golf Resort Women’s golf
Gurgaon, October 10: Nalini Singh Siwach maintained her steady form with a fine even-par round of 72 to take a two-shot lead at the end of the first round of the Hero-Classic Golf Resort Women’s Pro Golf, the eighth leg of the Indian women’s domestic Tour. She was two shots clear of Saaniya Sharma, who is still looking for her first win this season.
Smriti Mehra, winner of three titles this year, paid for her triple bogey eight on the par-5 third hole to finish at 75 and three behind the leader. She was tied for third with Vani Kapoor.
Nalini, who has already won once on the Hero-WGAI Tour, had three birdies and three bogeys. She bogeyed the seventh but got that back on the very next hole to turn in even par. On the back nine, a birdie on par-3 11th got her under par, before she gave away bogeys on 13th and 15th, but a closing birdie on 18th saw her finish at even par.
Saaniya Sharma, who has time and again given away the advantage, had one birdie against three bogeys in her two-over 74.
Vani Kapoor, winner last week at Delhi Golf Club, birdied the third, but then had back-to-back bogeys on fifth and sixth and then again on 15th and 16th. The rest were pars in her 75.
Neha Tripathi with one birdie, four bogeys and one double bogey carded 77 and was fifth, while Meghna Bal, Nikki Ponappa and Rani Sonti were sixth at 78.
On the Money List Smriti has won Rs. 7,67,750 this year, while Nalini has Rs. 6,98,000. Vani is just behind with Rs. 6,72,250 in third place.
This season Smriti has won three times, while Vani has won once. Sharmila and Nalini have won once each.
Tee times for Second round
8:30 AM: Seema Sobti (85) / Pallavi Jain (83)
8:40 AM: Preetinder Kaur (80)/Shraddhanjali Singh (80)/Ankita Tiwana (80)
8:50 AM: Priya Puri (79) / Rani Sonti (78) / Nikki Ponappa (78)
9:00 AM: Meghna (78) / Neha Tripathi(77) / Vani Kapoor (75)
9:10 AM: Smriti Mehra (75) / Saaniya Sharma(74) / Nalini S. Siwach(72)
To get more info on Hero Women’s Professional Golf Tour please visit us on our websitewww.wgai.co.in and join us on Facebook or follow us on Twitter or contact Abhoy Chattopadhyay / Deependra Chetri on +91 98113 25251 / +91 98111 82106.
–
Posted 1 minute ago by Nksagar
0
Add a comment
Oct
10
Description: SANOFI_Logo_H_2011_Quadri copie
Sanofi launches specially designed ‘made in India’ re-usable insulin pen – AllStar™
- Only multinational company in India with (a) a balanced portfolio of orals and insulins (b)one of the longest running national patient counseling programs and now…. (c) a chic indigenously manufactured re-usable insulin pen with 10-in-1 features, specially designed for Indians-
New Delhi, October 10, 2012: Sanofi India Limited (formerly known as Aventis Pharma Limited) announced today the launch of AllStar™, its first indigenously manufactured re-usable insulin pen. Developed especially for Indian patients by Sanofi’s Medical Device Development team at Frankfurt (architects of Sanofi’s award winning devices such as the Solostar®, Clickstar®, BGStar® and iBGStar™), AllStar™ is indicated for use of insulinized patients using Sanofi’s insulin portfolio. The AllStar™ re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the-art, unparalleled 10-in-1 features.
AllStar™ re-usable insulin pen’s 10-in-1 features – (1)Slim & discreet (2)Clear dose magnification window (3)Dose arrow on both sides (4)Bayonet cartridge lock (5)Short dial out distance (6)Penalty– free reverse dialing (7)Maximum dose dialing of 80 units (8)Audible click sound with every unit dialed and dispensed (9)Stops at 300 units (10)Non-rotating dial button during dispense Insulin therapy is a one of the cornerstones of diabetes management, and its efficacy in early as well as late-stage diabetes is well-established. Yet, the first choice of doctors in India for most diabetics has so far been to attempt sugar control through OADs (Oral Anti-Diabetics), diet control, exercise and lifestyle changes. One of the key reasons for delaying control through insulin is the resistance and fear in patients, of taking injections daily, particularly self-administering the same. AllStar™ is custom-made for patients in India. AllStar™ will help improve both insulin initiation and compliance; and bring ease and reassurance to the lives of Indian patients, giving them the convenience of international standards at an affordable price.
Announcing the launch of AllStar™, Dr. Shailesh Ayyangar, Managing Director, Sanofi India & Vice President South Asia, Group Sanofi, said, “Sanofi has always been at the forefront of diabetes research and development and AllStar™ is a testament to our patient-centric approach. For almost three years, Sanofi’s scientists worked closely with our team here to develop a device that was ‘made in India, for India’.”
Dr. Ayyangar further added “AllStar™ heralds a new era of indigenous device manufacturing for Sanofi India, which we hope to utilize for other devices in future.
‘The launch of AllStar™ is a significant milestone in Sanofi India’s diabetes growth story, and also underlines the Sanofi Group’s focus on diabetes, emerging markets and our regionalized approach to finding solutions that are adapted to local needs.“
Commenting on the genesis of this development, Susheel Umesh, Head of Commercial Operations, Sanofi India, said “In line with our mission to truly become a 360 degree partner in diabetes management, we always start with the patient, to understand from them and their physicians what their real needs and expectations are, and work towards introducing solutions to address those needs and expectations.
‘AllStar™ is the result of a successful collaborative multi-country effort within the Sanofi Group that brought together technology, resources and intellectual capital to help Sanofi India develop a pen that its patients aspire for; one that combines convenience and affordability.”
Through a perception study done in July 2011[i], Sanofi found that the most valued features of an insulin pen are ease of use, readability of dose, reverse dialing and high quality. At that time, the study group perceived AllStar™ as better than other pens in the market on most parameters, with ease of use, lighter, smaller and slimmer design being the key differentiators.
All Star™
Speaking on the AllStar™ pen’s technical aspects, Dr. Volker Korger, Head – Diabetes Device Projects, (MED Frankfurt) Sanofi, shared that, “AllStar™ is a combination of sleek design styling and sophisticated technology. We brought together Sanofi’s award winning Solostar® design team in Germany and UK to make AllStar™, the lightest reusable insulin pen in India. The German team contributed its renowned expertise in quality medical devices, and from Taiwan we included accurate tooling, as in a device such as this, extraordinary accuracy is most vital in even the smallest of components. Finally, the manufacturing is being done in India – well recognized today for producing high-precision components.”
With close to 62 million diabetic patients, of whom many are either undiagnosed or uncontrolled because of poor compliance, diabetes is a major health problem in India. Given the social and economic impact of diabetes, it is important to make concentrated efforts to help create awareness about diagnosis, management and treatment of diabetes and further, to re-inforce among physicians and patients the necessity of preventing complications in diabetic patients through early insulin therapy.
Dr. S.K Wangnoo, Senior Consultant, Endocrinology and Diabetes, Apollo Centre for Obesity Diabetes and Endocrinology, Indraprastha Apollo Hospitals said, “Various studies have established the importance of early insulin therapy in the management of diabetes. Key to ensuring better compliance and management at the patient level is providing them with convenient solutions. AllStar™, a state-of-the art device for the administration of insulin, will provide Indian patients with the ease of self-administration, and bring comfort and efficacy into their lives.”
AllStar™ is supported by a patient support team of certified diabetes educators to assist patients under guidance of treating physicians, and a toll-free number. The re-useable AllStar™ will be available for use with Sanofi’s insulins – Lantus® and Insuman® – on doctor’s prescription at all leading chemists and distributors across India.
Susheel Umesh added, “We are striving to help people manage the complex challenge of diabetes by delivering and enabling access to a range of innovative, personalized solutions, because we want people to live ‘beyond’ diabetes, to achieve aspirations and make the most of everyday!”
About Diabetes: Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million persons worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. World Health Organization (WHO) estimates that India had 32 million diabetic patients in the year 2000 which would increase to 80 million by 2030. The International Diabetes Federation has reported that the 50.8 million diabetic patients in India in 2010 would rise to 87 million by 2030. These observations clearly evince that diabetes has become a major health problem in India.
About Sanofi: Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
In India, Sanofi operates through five entities − Sanofi India Limited (previously known as Aventis Pharma Limited), Sanofi-Synthelabo (India) Limited, Sanofi Pasteur India Private Limited, Shantha Biotechnics Limited and Genzyme India Private Limited.
About Sanofi Diabetes:
With a century of experience in Diabetes, Sanofi stands committed to improve the lives of people with diabetes. Through its various incarnations, Sanofi has led the field in insulin manufacturing as well as in diabetes research and development: from the first manufacture of insulin (one of its predecessor companies, Hoechst, was the original company to produce insulin in 1923, after the discovery by Frederic Banting and Charles Best in Canada that insulin could be extracted and initially used to treat children with Type 1 diabetes ) through to the development of Lantus® (the first company to produce a long-acting basal insulin analogue) launched a decade ago and up to the present day, where it is now investigating the possibility of regenerating the insulin-producing cells in the body.
In addition to its insulin products, Sanofi has a range of award-winning delivery devices, oral therapies – on the market and in development – and innovative blood glucose monitoring systems, so that, together with its personalized services, Sanofi can offer a patient-centric partnership to people with diabetes.
Aligned to the Sanofi Group’s commitment to diabetes, Sanofi Diabetes India strives to become a true 360 degree partner for patients and healthcare professionals, offering a complete range of innovative and integrated solutions.
MEDIA CONTACT:
Ms. Ambereen SHAH Account Director Tel: +91 9717022731 Email: bhavna.thapar@edelman.com Shilpy ROY Account Manager Tel: +91 9650111652 Email: shilpy.roy@edelman.com Sanofi India Agency: Edelman India
Ruchita MEHRA
Head – External Communications
Tel: +91 98209 86056/ 022-28278233
Email: ruchita.mehra@sanofi.com
Nikita MERCHANT
Assistant Manager – Marketing Communications
Tel: +91 9819071300
Posted 17 minutes ago by Nksagar
Oct
AirAsia Japan Launches International Flights to Korea
Fly from Narita to Seoul from as low as KRW2,000 one way
TOKYO, 10 October 2012 – AirAsia Japan, an affiliate of the world’s best low cost carrier for four consecutive years is set to strengthen its position as an industry leader with the announcement of its international route to Seoul (Incheon), Korea. In conjunction with the international flight debut celebration, AirAsia Japan is having a special promotion with seats from as low as KRW2,000* up for grabs.
The Narita to Seoul (Incheon) route will begin operations on October 28th 2012 with daily flights operating from Narita International Airport.
Seats between the Narita – Seoul (Incheon) route are from as low as KRW30,000 one way, inclusive of airport tax and fees. Guests are able to grab the special promotional fares exclusively at www.airasia.com beginning 10pm (GMT+8) on 10 October till 17 October 2012 for the travel period from 28th October – 30th March 2013.
The new route announcement was made simultaneously by AirAsia Group CEO Tony Fernandes in Seoul and AirAsia Japan CEO Kazuyuki Iwakata in Tokyo.
Tony said, “This is a great day for all of us, and an even greater day for the consumers & air travelers in Korea. With AirAsia’s low fare, everyone can now travel to more places more often. AirAsia Japan’s announcement of this international route today is a dream come true for us, and I am looking forward to see the Narita – Incheon flights begin operations. Congratulations to Kazuyuki and his team for making Japanese and Korean skies friendlier and more affordable.”
Kazuyuki said, “We are extremely happy and proud to enable so many guests to fly and enjoy the AirAsia experience since we started operations about three months ago. The announcement of our new international routes to Korea gives me much pleasure as AirAsia Japan can now further expand the AirAsia Group’s existing extensive route network, connecting Japan and other countries in Asia. It makes much sense to begin our international flights to Korea, our next-door neighbor and I am sure that this will further enable and inspire more people to travel to international destinations as the flights take only about 2 hours from Narita to Incheon.
AirAsia Japan’s international flights will also be operated on Airbus A320 aircraft with a capacity of 180 seats, similar to its domestic flights.
Follow AirAsia on social media via Facebook (http://www.facebook.com/AirAsiaKorea) and Twitter (http://www.twitter.com/airasiakr) for latest updates, promotions, activities and more.
*KRW2,000 base fare is not inclusive of airport tax and fees.
Tokyo（Narita）⇒Seoul（Incheon）
Seoul（Incheon）⇒Tokyo（Narita）
Flight No.
10/28～3/30
Flight No.
10/28～3/30
ETD
ETA
ETD
ETA
JW 0893
14:15
17:00
JW 0892
17.45
20:00
Photo captions:
Photo 1 – AirAsia Group CEO Tony Fernandes and AirAsia Group Head of Commercial Kathleen Tan (5th from left) announcing AirAsia Japan’s new international route in Seoul, Korea
Photo 2 – AirAsia Group CEO Tony Fernandes and AirAsia flight attendants at AirAsia Japan’s Narita – Seoul international route launch in Seoul, Korea
Photo 3 – AirAsia Japan CEO with AirAsia flight attendants during the Narita-Seoul international flight announcement in Tokyo. AirAsia Group CEO Tony Fernandes made a simultaneous announcement in Seoul, Korea
About AirAsia Japan & AirAsia Group
AirAsia Japan is a joint-venture between ANA and AirAsia, which was established in August 2011. As a low-cost carrier (LCC) based in Narita International Airport, it operates domestic routes to Sapporo, Fukuoka, & Okinawa since August 2012 and will start to operate international routes to Seoul and Busan in Korea in October 2012. AirAsia Japan’s objective is to develop the LCC market in Japan, generating new demand with the aim of making affordable and quality travel available to all. AirAsia Japan is part of the AirAsia Group, the leading and largest low-cost carrier in Asia servicing the most extensive network with over 150 routes. Within 10 years of operations, AirAsia has carried over 150 million guests and grown its fleet from just two aircraft to approximately 106. AirAsia was named the World’s Best Low Cost Airline in the annual World Airline Survey by Skytrax for four consecutive years (2009, 2010, 2011,2012).
Comments
Post a Comment